Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight
Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
Company Research
Source: PR Newswire
The expansion of the cholestatic pruritus market across the US will be driven by the introduction of innovative therapies, Linerixibat, Volixibat, and TH104, among others. Furthermore, the rising prevalence of cholestatic pruritus, driven by increased disease awareness, improved diagnostic capabilities, earlier detection of underlying liver disorders, and an aging population, will contribute to greater demand for effective treatments. LAS VEGAS, Nov. 4, 2025 /PRNewswire/ -- DelveInsight's Cholestatic Pruritus Market Insights report includes a comprehensive understanding of current treatment practices, cholestatic pruritus emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into the US. Cholestatic Pruritus Market S
Show less
Read more
Impact Snapshot
Event Time:
CMMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMMB alerts
High impacting Chemomab Therapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CMMB
News
- Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of GastroenterologyGlobeNewswire
- Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Chemomab to Participate in Oppenheimer’s Movers in Rare Disease SummitGlobeNewswire
- Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat